spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  angiogenesis inhibitor 

 HSMN NewsFeed - 26 May 2020
Elevar Therapeutics Appoints Mark Gelder, M.D. as Global Head of Medical Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Dec 2019
European Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Oct 2019
EVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Jun 2018
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Feb 2016
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 21 Nov 2012
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2012
Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2012
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2011
ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Nov 2009
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Mar 2009
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2008
ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Nov 2008
Lilly Completes Cash Tender Offer for ImClone Systems
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Oct 2008
ImClone Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2008
OXiGENE, Inc. Names John A. Kollins as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Oct 2008
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2008
ImClone Announces Merger Agreement with Eli Lilly at $70 Per Share
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Sep 2008
ERBITUX(R) Now Available in Japan for Use in Treating Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2008
ImClone Provides Update on Pivotal Phase 3 CRYSTAL Study in First-Line Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2008
ImClone Systems Issues Statement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Sep 2008
ImClone Submits Supplemental Biologics License Application for ERBITUX(R) in First-Line Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Aug 2008
ImClone Systems Issues Statement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Jul 2008
ERBITUX(R) (Cetuximab) Receives Approval in Japan for Use in Advanced Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jul 2008
ImClone Announces Changes in Commercial Organization Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2008
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2008
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2008
ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2008
ImClone Appoints Kenneth J. Zuerblis Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2008
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jan 2008
American Academy of Ophthalmology Mourns Loss of Judah Folkman, MD, Pioneering Researcher
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2008
EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Dec 2007
EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 29 Nov 2007
Published Data Suggest That ERBITUX(R) Enables Complete Surgical Resection of Colorectal Liver Metastases in Patients Previously Refractory to Conventional Systemic Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2007
ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2007
EntreMed Appoints Senior Vice President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Oct 2007
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Sep 2007
ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2007
EntreMed Raises $20 Million to Support Clinical Development Program
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
Biopharmaceuticals Oncology Litigation Licensing
 HSMN NewsFeed - 10 Sep 2007
EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Aug 2007
Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2007
ImClone Systems Appoints John H. Johnson Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jul 2007
ImClone Systems Appoints Thomas F. Deuel to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jun 2007
FDA Accepts and Grants Priority Review of ERBITUX(R) (Cetuximab) sBLA for Overall Survival in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 May 2007
ImClone Systems Appoints Jules Haimovitz to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Apr 2007
Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Feb 2007
ImClone Systems Opts-out of Development Agreement with UCB to Focus Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121B
Biopharmaceuticals
 HSMN NewsFeed - 5 Feb 2007
ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jan 2007
AVEO Acquires Clinical Stage Anti-Cancer Compound From Kirin
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 20 Dec 2006
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2006
Carl C. Icahn Appointed Chairman of ImClone Systems
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Oct 2006
ImClone Systems Appoints Peter S. Liebert, M.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Oct 2006
ImClone Systems Directors Urge Stockholders to Reject Carl Icahn's Efforts to Opportunistically Seize Control of the Company
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2006
Biotica Enters into a Research and License Agreement with Wyeth for Novel Rapamycin Analogs
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Sep 2006
ImClone Systems Promotes Ana I. Stancic to Senior Vice President, Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Sep 2006
ImClone Systems Issues Statement on Court Ruling in Litigation against Yeda
Biopharmaceuticals Oncology Licensing Litigation
 HSMN NewsFeed - 20 Jul 2006
ImClone Systems and Merck KGaA Amend and Supplement ERBITUX Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Jul 2006
Nascent Pharmaceuticals Adds Joanna Horobin, M.D., to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2006
ImClone Systems Names Elizabeth Yamashita Vice President, Regulatory CMC and Operations
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 129

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 129 additional stories matching:
angiogenesis inhibitor
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!